Pregnane X receptor as a therapeutic target for cholestatic liver injury

Cholestatic liver injury (CLI) is caused by toxic bile acids (BAs) accumulation in the liver and can lead to inflammation and liver fibrosis. The mechanisms underlying CLI development remain unclear, and this disease has no effective cure. However, regulating BA synthesis and homeostasis represents a promising therapeutic strategy for CLI treatment. Pregnane X receptor (PXR) plays an essential role in the metabolism of endobiotics and xenobiotics via the transcription of metabolic enzymes and transporters, which can ultimately modulate BA homeostasis and exert anticholestatic effects. Furthermore, recent studies have demonstrated that PXR exhibits antifibrotic and anti-inflammatory properties, providing novel insights into treating CLI. Meanwhile, several drugs have been identified as PXR agonists that improve CLI. Nevertheless, the precise role of PXR in CLI still needs to be fully understood. This review summarizes how PXR improves CLI by ameliorating cholestasis, inhibiting inflammation, and reducing fibrosis and discusses the progress of promising PXR agonists for treating CLI.

Automated summary

Cholestatic liver injury (CLI) is a disease caused by the accumulation of toxic bile acids (BAs) in the liver, resulting in inflammation and liver fibrosis. The regulation of BA synthesis and homeostasis, particularly through the activation of the Pregnane X receptor (PXR), has shown promise in treating CLI. PXR plays a crucial role in the metabolism of endobiotics and xenobiotics, ultimately modulating BA homeostasis and exerting anti-cholestatic effects. Recent studies have also demonstrated the antifibrotic and anti-inflammatory properties of PXR, providing new insights into CLI treatment.